Eponemin, a self-developed Class 1 innovative drug, acts as an agonist for DR4/DR5. It binds and activates these receptors on the surface of tumor cells, initiating the intracellular caspase cascade via the extrinsic apoptosis pathway, thereby exerting antitumor effects (Author Anonymous, 2025a; Author Anonymous, 2025b). The gene discussed is TNFRSF10B; the disease is neoplasm.